These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 9225037)

  • 1. African horsesickness virus VP7 sub-unit vaccine protects mice against a lethal, heterologous serotype challenge.
    Wade-Evans AM; Pullen L; Hamblin C; O'Hara R; Burroughs JN; Mertens PP
    J Gen Virol; 1997 Jul; 78 ( Pt 7)():1611-6. PubMed ID: 9225037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VP7 from African horse sickness virus serotype 9 protects mice against a lethal, heterologous serotype challenge.
    Wade-Evans AM; Pullen L; Hamblin C; O'Hara RS; Burroughs JN; Mertens PP
    Arch Virol Suppl; 1998; 14():211-9. PubMed ID: 9785508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant baculovirus-synthesized African horsesickness virus (AHSV) outer-capsid protein VP2 provides protection against virulent AHSV challenge.
    Roy P; Bishop DH; Howard S; Aitchison H; Erasmus B
    J Gen Virol; 1996 Sep; 77 ( Pt 9)():2053-7. PubMed ID: 8811002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective immunization of horses with a recombinant canarypox virus vectored vaccine co-expressing genes encoding the outer capsid proteins of African horse sickness virus.
    Guthrie AJ; Quan M; Lourens CW; Audonnet JC; Minke JM; Yao J; He L; Nordgren R; Gardner IA; Maclachlan NJ
    Vaccine; 2009 Jul; 27(33):4434-8. PubMed ID: 19490959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization with VP2 is sufficient for protection against lethal challenge with African horsesickness virus Type 4.
    Stone-Marschat MA; Moss SR; Burrage TG; Barber ML; Roy P; Laegreid WW
    Virology; 1996 Jun; 220(1):219-22. PubMed ID: 8659117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Full protection against African horsesickness (AHS) in horses induced by baculovirus-derived AHS virus serotype 4 VP2, VP5 and VP7.
    Martínez-Torrecuadrada JL; Díaz-Laviada M; Roy P; Sánchez C; Vela C; Sánchez-Vizcaíno JM; Casal JI
    J Gen Virol; 1996 Jun; 77 ( Pt 6)():1211-21. PubMed ID: 8683209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation of recombinant African horse sickness virus VP7 antigen via a simple method and validation of a VP7-based indirect ELISA for the detection of group-specific IgG antibodies in horse sera.
    Maree S; Paweska JT
    J Virol Methods; 2005 Apr; 125(1):55-65. PubMed ID: 15737417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination of mice with a modified Vaccinia Ankara (MVA) virus expressing the African horse sickness virus (AHSV) capsid protein VP2 induces virus neutralising antibodies that confer protection against AHSV upon passive immunisation.
    Calvo-Pinilla E; de la Poza F; Gubbins S; Mertens PP; Ortego J; Castillo-Olivares J
    Virus Res; 2014 Feb; 180():23-30. PubMed ID: 24333835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48h before, or 48h after challenge.
    Calvo-Pinilla E; de la Poza F; Gubbins S; Mertens PP; Ortego J; Castillo-Olivares J
    Antiviral Res; 2015 Apr; 116():27-33. PubMed ID: 25643968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination with recombinant Modified Vaccinia Ankara (MVA) viruses expressing single African horse sickness virus VP2 antigens induced cross-reactive virus neutralising antibodies (VNAb) in horses when administered in combination.
    Manning NM; Bachanek-Bankowska K; Mertens PPC; Castillo-Olivares J
    Vaccine; 2017 Oct; 35(44):6024-6029. PubMed ID: 28438410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of competitive ELISA for serodiagnosis on African horsesickness virus using baculovirus expressed VP7 and monoclonal antibody.
    Kweon CH; Kwon BJ; Ko YJ; Kenichi S
    J Virol Methods; 2003 Oct; 113(1):13-8. PubMed ID: 14500122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The immunogenicity of recombinant vaccines based on modified Vaccinia Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens depends on the levels of expressed VP2 protein delivered to the host.
    Calvo-Pinilla E; Gubbins S; Mertens P; Ortego J; Castillo-Olivares J
    Antiviral Res; 2018 Jun; 154():132-139. PubMed ID: 29678552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Production of monoclonal antibodies binding to the VP7 protein of African horse sickness virus.
    Luciani M; Armillotta G; Ciarelli A; Ulisse S; Teodori L; Bortone G; Giamboi A; Monaco F; Tittarelli M; Di Ventura M; Iannetti L; Podaliri Vulpiani M; Di Febo T
    J Virol Methods; 2019 Aug; 270():131-136. PubMed ID: 31095974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serological and virological responses in mules and donkeys following inoculation with African horse sickness virus serotype 4.
    el Hasnaoui H; el Harrak M; Zientara S; Laviada M; Hamblin C
    Arch Virol Suppl; 1998; 14():29-36. PubMed ID: 9785493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ns1 is a key protein in the vaccine composition to protect Ifnar(-/-) mice against infection with multiple serotypes of African horse sickness virus.
    de la Poza F; Calvo-Pinilla E; López-Gil E; Marín-López A; Mateos F; Castillo-Olivares J; Lorenzo G; Ortego J
    PLoS One; 2013; 8(7):e70197. PubMed ID: 23894615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Passive transfer and rate of decay of maternal antibody against African horse sickness virus in South African Thoroughbred foals.
    Crafford JE; Lourens CW; Gardner IA; Maclachlan NJ; Guthrie AJ
    Equine Vet J; 2013 Sep; 45(5):604-7. PubMed ID: 23294121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. African horse sickness virus (AHSV) with a deletion of 77 amino acids in NS3/NS3a protein is not virulent and a safe promising AHS Disabled Infectious Single Animal (DISA) vaccine platform.
    van Rijn PA; Maris-Veldhuis MA; Potgieter CA; van Gennip RGP
    Vaccine; 2018 Apr; 36(15):1925-1933. PubMed ID: 29525278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VP2 Exchange and NS3/NS3a Deletion in African Horse Sickness Virus (AHSV) in Development of Disabled Infectious Single Animal Vaccine Candidates for AHSV.
    van de Water SG; van Gennip RG; Potgieter CA; Wright IM; van Rijn PA
    J Virol; 2015 Sep; 89(17):8764-72. PubMed ID: 26063433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of the major core antigen VP7 of African horsesickness virus by a recombinant baculovirus and its use as a group-specific diagnostic reagent.
    Chuma T; Le Blois H; Sánchez-Vizcaíno JM; Diaz-Laviada M; Roy P
    J Gen Virol; 1992 Apr; 73 ( Pt 4)():925-31. PubMed ID: 1378881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Further studies on the efficacy of an inactivated African horse sickness serotype 4 vaccine.
    House JA; Lombard M; Dubourget P; House C; Mebus CA
    Vaccine; 1994 Feb; 12(2):142-4. PubMed ID: 8147096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.